PMC:7558914 / 11156-11360 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"241","span":{"begin":55,"end":63},"obj":"Species"},{"id":"242","span":{"begin":163,"end":171},"obj":"Species"},{"id":"263","span":{"begin":76,"end":85},"obj":"Disease"},{"id":"264","span":{"begin":177,"end":186},"obj":"Disease"}],"attributes":[{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"Tax:9606"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"Tax:9606"},{"id":"A263","pred":"tao:has_database_id","subj":"263","obj":"MESH:D011014"},{"id":"A264","pred":"tao:has_database_id","subj":"264","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"2 (6/15, 40%) were the most recommended treatments for patients with severe pneumonia. Most protocols showed a preference for dual or triple antiviral therapy for patients with pneumonia. Further details "}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T20","span":{"begin":76,"end":85},"obj":"Phenotype"},{"id":"T21","span":{"begin":177,"end":186},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"2 (6/15, 40%) were the most recommended treatments for patients with severe pneumonia. Most protocols showed a preference for dual or triple antiviral therapy for patients with pneumonia. Further details "}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T72","span":{"begin":87,"end":187},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"2 (6/15, 40%) were the most recommended treatments for patients with severe pneumonia. Most protocols showed a preference for dual or triple antiviral therapy for patients with pneumonia. Further details "}